title: [Eruptive naevi associated with octreotide treatment].
abstract: BACKGROUND
  Octreotide is a synthetic octapeptide having properties related to those of natural somatostatin, a hypothalamic hormone. We report a case of eruptive naevus in patients treated with octreotide.
  
  
  METHODS
  A 52-year-old man consulted for multiple achromic naevi of recent onset. He was undergoing treatment with octreotide 30 mg per month for hepatic metastases in a setting of operated colonic carcinoid tumor. Since the start of this treatment, he had presented an efflorescence of diffuse naevus comprising over 200 lesions, certain of which were highly atypical. Annual follow-up was carried out. Ten years later, the patient was still alive and undergoing octreotide therapy at the same dose. The number of naevi had stabilized and there was no evidence of melanoma.
  
  
  CONCLUSIONS
  Eruptions of naevi are rare; they may occur at the sites of lesions in bullous diseases or during immunodepression (malignant or drug induced, HIV infection). There are questions concerning possible stimulation of naevus cells and the risk of onset of melanoma. Routine monitoring of pigmented lesions is thus necessary in patients treated with octreotide.
authors: Cabinet de dermatologie, Saint-Étienne, France. jean.loic.michel@wanadoo.fr
authors: J-L
authors: JL
authors: Michel
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D003937:Diagnosis, Differential; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008544:Melanocytes / Q000473:pathology; D008545:Melanoma / Q000175:diagnosis / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D009508:Nevus, Pigmented / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D015282:Octreotide / Q000009:adverse effects* / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology / Q000556:secondary
chemical_list: D018931:Antineoplastic Agents, Hormonal; D015282:Octreotide